SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Foster, R
Right arrow Articles by D’Cruz, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foster, R
Right arrow Articles by D’Cruz, D
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Primary systemic vasculitis: treatment of difficult cases

R Foster

Department of Immunology, St Thomas’ Hospital, London, UK

E Rosenthal

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK

S Marques

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK

P Vounotrypidis

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK

S Sangle

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK

D D’Cruz

Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK, david.d'cruz{at}kcl.ac.uk

The primary systemic necrotizing vasculitides are a severe group of diseases, which untreated have a high mortality. The majority respond to treatment with high dose steroids and cyclophosphamide, however a significant proportion of those treated suffer morbidity due to the side effects of these agents, and a number of patients are refractory to treatment. We review and discuss alternative and emerging treatment options for patients who fail or cannot tolerate conventional therapy. An interesting subgroup of patients with systemic vasculitis and antiphospholipid antibodies provides an additional diagnostic and therapeutic challenge. We review what is known about this subgroup, and suggest screening for antiphospholipid antibodies in all patients with systemic vasculitis.

Key Words: antiphospholipid antibodies • anti-TNF alpha therapy • mycophenolate mofetil • rituximab • vasculitis

Lupus, Vol. 15, No. 3, 143-147 (2006)
DOI: 10.1191/0961203306lu2277rr
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement